Pair Name | Luteolin, IL-24 | |||
Partner Name | Luteolin | |||
Disease Info | [ICD-11: 2C12] | Hepatocellular carcinoma | Investigative | |
Biological Phenomena | Induction-->Apoptosis | |||
Gene Regulation | Up-regulation | Cleavage | CASP3 | hsa836 |
Up-regulation | Cleavage | CASP8 | hsa841 | |
Up-regulation | Cleavage | PARP1 | hsa142 | |
In Vitro Model | L-02 | Human papillomavirus-related cervical adenocarcinoma | Homo sapiens (Human) | CVCL_6926 |
MHCC97-H | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_4972 | |
Hep-G2 | Hepatoblastoma | Homo sapiens (Human) | CVCL_0027 | |
PLC/PRF/5 | Adult hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0485 | |
Hep 3B2.1-7 | Childhood hepatocellular carcinoma | Homo sapiens (Human) | CVCL_0326 | |
In Vivo Model | The xenograft model was established by subcutaneously injection of 4×10⁶ MHCC97-H cells into the right flank of these female BALB/c nude mice (5 weeks old). | |||
Result | These data confirm that the synergistic mechanism of VV-IL-24 and luteolin elicits a stronger tumor growth inhibition than any single therapy. Thus, the combination of VV-IL-24 and luteolin could provide the basis for preclinical research in the treatment of liver cancer. |